Mural Oncology

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

Woman,Hand,Holding,Plus,Icon,For,The,Healthcare,Medical,Icon.

News

Movers

MURA

Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company&#39;s announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin exploring strategic alternatives. 

Mural Oncology Shares Surge As Company Explores Strategic Alternatives: What&#39;s Going On?

Wall,Street,And,New,Street.,New,York.,Usa.,06-30-2012

Earnings

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

APLD

GOVX

RZLV

SKYE

SPRB

Crude Oil Moves Lower; Citigroup Posts Upbeat Results

Nvidia, Meta Platforms, Oracle, Palantir, And Tesla: 5 Trending Stocks Amid Monday's Market Meltdown

Equities

BULL

SNYR

Nasdaq Surges 100 Points; Bank of America Earnings Top Views

Mural Oncology PLC

Murakami Corp

Murano Global Investments PLC - Ordinary Shares

Murano Global Investments PLC

MURATA MFG INC ORD by Murata Manufacturing Inc.

Murata Manufacturing Co Ltd

MURATA MFG INC UNSP/ADR by Murata Manufacturing Inc.

Press Releases

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Health Care

Mural Oncology to Participate in Two Upcoming Investor Conferences

Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress

Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts

Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones

Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer

Mural Oncology Announces Plans to Explore Strategic Alternatives

Agenus

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharma

bluebird bio

Celularity

Connect Biopharma Holdings Limited - American Depositary Shares

Connect Biopharma Hldgs

Fortress Biotech

FibroBiologics

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

MAIA Biotechnology

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OKYO Pharma

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PepGen

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

Spero Therapeutics

Sutro Biopharma

Xilio Therapeutics

HC Wainwright & Co.

Raymond James

Rodman & Renshaw

Morgan Stanley

Comments

Mural Oncology

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell